Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 8.95B -25.3% |
| Revenue (ttm) | 4.77B +6.0% |
| Net Income | 480.47M +29.3% |
| EPS | 0.56 +31.8% |
| Shares Out | 841.19M |
| PE Ratio | 19.12 |
| Forward PE | 12.48 |
| Dividend | 0.29 (2.75%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 1,964,843 |
| Open | 1,056.00 |
| Previous Close | 1,052.00 |
| Day's Range | 1,049.00 - 1,066.00 |
| 52-Week Range | 1,042.00 - 1,441.50 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | 1,284.76 (+20.75%) |
| Earnings Date | Nov 5, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,285p, which is an increase of 20.75% from the latest price.
News
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
Smith+Nephew and Imperial College London have launched a five-year partnership to deliver research for robotic surgery for musculoskeletal conditions.
Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a breakthrough in RF resection technology for hip with its new FLOW FLEXTEND COBLATION Wand. Designed as an exte...
Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week
Canton, Ohio—As thousands of football fans descend on Canton for the 2026 Pro Football Hall of Fame Enshrinement Week, Smith+Nephew, the Global medical technology company, will join the celebration wi...
Smith & Nephew Earnings Call Transcript: Q2 2026
Q2 revenue growth was below expectations at 1.6%, with strong Sports Medicine and ENT offset by U.S. Orthopaedics and Advanced Wound Bioactives softness. Profitability remained robust, supported by efficiency savings and tariff refunds, and full-year profit guidance is maintained despite a reduced revenue outlook.
Smith & Nephew Quarterly report: Q2 2026
Smith & Nephew has published its Q2 2026 quarterly earnings report on August 4, 2026.
Smith & Nephew Slides: Q2 2026
Smith & Nephew has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
UK's Smith+Nephew cuts annual revenue expectations
British medical products company Smith+Nephew cut its full-year revenue growth forecast on Tuesday, as continued weakness in its orthopaedics unit in the U.S, its largest market, weighed ...
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single...
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of ...
Smith & Nephew Transcript: Investor update
The event showcased a robust innovation pipeline across wound care, sports medicine, orthopedics, and enabling technologies, with a focus on ASC efficiency and data-driven solutions. Key platforms like CORI, Landmark, AETOS, and TESSA are positioned to drive growth, supported by strong clinical evidence and surgeon advocacy.
Smith & Nephew Slides: Investor update
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, ...
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform d...
Smith & Nephew Slides: Investor presentation
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Smith & Nephew Earnings Call Transcript: Q1 2026
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
Smith & Nephew Slides: Q1 2026
Smith & Nephew has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Smith & Nephew Earnings release: Q1 2026
Smith & Nephew released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annu...
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...
Smith & Nephew Slides: Investor presentation
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed...
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...
Smith & Nephew Earnings Call Transcript: Q4 2025
Strong FY2025 results featured 5.3% underlying revenue growth, 160 bps margin expansion, and a 52.5% increase in free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and disciplined capital allocation driving performance.
Smith & Nephew Annual report: Q4 2025
Smith & Nephew has published its Q4 2025 annual report on March 2, 2026.